Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Title:
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Author:
Chan, A.T.C. Lee, V.H.F. Hong, R.-L. Ahn, M.-J. Chong, W.Q. Kim, S.-B. Ho, G.F. Caguioa, P.B. Ngamphaiboon, N. Ho, C. Aziz, M.A.S.A. Ng, Q.S. Yen, C.-J. Soparattanapaisarn, N. Ngan, R.K.-C. Kho, S.K. Tiambeng, M.L.A. Yun, T. Sriuranpong, V. Algazi, A.P. Cheng, A. Massarelli, E. Swaby, R.F. Saraf, S. Yuan, J. Siu, L.L.
Appeared in:
Annals of oncology
Paging:
Volume 34 () nr. 3 pages 251-261
Year:
2023
Contents:
Publisher:
Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., The Author(s).